显著的全性路径介导Ca2+依赖的NMDA受体对开放通道阻断剂敏感度的增加
Mae G Weaver1, Jamie A Abbott1, Gabriela K Popescu1
1Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, SUNY; Buffalo, New York, 14226, USA.
Biophysical journal
|February 6, 2026
概括
细胞外 (Ca2+) 水平影响NMDA受体对Mg2+和美曼丁等开放通道阻断剂的敏感性. 这些Ca2+效应是由不同的细胞内和细胞外机制调解的,这可能解释了NMDA受体药物的不同临床结果.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- NMDA受体对中枢神经系统的功能至关重要,它们调解富含Ca2+的电流.
- 细胞外Ca2+波动会影响NMDA受体活性和门.
- 像胺和美曼丁这样的NMDA受体抑制剂在临床上具有重要意义.
研究的目的:
- 研究细胞外Ca2+度如何影响NMDA受体对开放通道阻断剂的敏感性.
- 阐明NMDA受体阻断的Ca2+调节的具体机制.
主要方法:
- 补丁的电生理学 补丁的电生理学
- 动态分析 动态分析
- 局部导向的突变发生.
主要成果:
- 细胞外Ca2+增强了NMDA受体对Mg2+和记忆素阻断物的敏感性,但不是胺.
- 调节内细胞Ca2+和calmodulin所需的孟坦丁阻断剂的Ca2+调节.
- 在Ca2+调节的Mg2+阻断中,涉及到细胞外残留物GluN1-D658.
结论:
- 细胞外Ca2+差异调节NMDA受体对各种开放通道阻断剂的敏感性.
- 独特的分子机制是对NMDA受体阻断的Ca2+影响的基础.
- 这些发现可能解释NMDA受体对抗剂药物的不同临床特征.
相关概念视频
Receptor-mediated Endocytosis
111.0K
Overview
111.0K
Receptor-mediated Endocytosis
7.9K
Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...
7.9K
Cooperative Allosteric Transitions
8.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Antiepileptic Drugs: Sodium Channel Blockers
1.8K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.8K
Antiepileptic Drugs: Calcium Channel Blockers
1.3K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550


